mCRPC

Switching from Abiraterone Plus Prednisone to Abiraterone Plus Dexamethasone Can Extend Its Effectiveness

Switching from Abiraterone Plus Prednisone to Abiraterone Plus Dexamethasone Can Extend Its Effectiveness

A timed steroid switch from prednisone to dexamethasone appears to be a safe and non‐expensive way of obtaining long‐term responses to Zytiga in selected men with metastatic castrate resistant prostate cancer (mCRPC).

Role and Precautions About to the Use of Bisphosphonate Drugs

Once a man with metastatic prostate cancer becomes castrate resistant (mCRPC) it is common to add a bisphosphonate like injectable zoledronic acid (Zometa) or denosumab (Xgeva) to his drug regimen.  Like all other drugs, bisphosphonates have unwanted side effects, some which can be mediated.